Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868613 | 0.87 | FGFR1 (0.49) | FGFR1FGFR2FGFR3DRD2SIGMAR1 | |
| SCHEMBL2869212 | 0.87 | HTR7 (0.43) | FGFR1DRD2 | |
| SCHEMBL2872630 | 0.85 | HTR7 (0.42) | FGFR1 | |
| SCHEMBL2857668 | 0.84 | HRH4 (0.45) | XDHDRD3HRH3HRH4HTR1A | |
| SCHEMBL14375313 | 0.84 | XDH (0.43) | XDHFGFR1HRH3SIGMAR1ESR1 | |
| SCHEMBL2865177 | 0.82 | FGFR1 (0.45) | XDHFGFR1FGFR2FGFR3HRH3 | |
| SCHEMBL2856171 | 0.80 | FGFR1 (0.38) | FGFR1DRD3HTR1ADRD2 | |
| SCHEMBL2868766 | 0.79 | KDM4E (0.51) | FGFR1FGFR2FGFR3DRD2SIGMAR1 | |
| SCHEMBL2870232 | 0.79 | MAOA (0.43) | XDHFGFR1FGFR2FGFR3SIGMAR1 | |
| SCHEMBL2861337 | 0.79 | KDM4E (0.50) | FGFR1FGFR2FGFR3HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1719771-A1 | PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | MAP3K20, MAP4K5, MAP4K3 | XDH 389/4885FGFR1 201/4885FGFR2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.